GlobeNewswire Inc.··DelveinsightMyasthenia Gravis Market Poised for Transformation With 8 Late-Stage Drug Candidates
Generalized myasthenia gravis market valued at $5.9B in 2025, projected to grow 9.1% annually through 2036 as eight promising late-stage therapies advance.
NVSAZNREGNMKKGYROIV+3clinical trialsautoimmune disease